Pet Cancer Therapeutics

Global Pet Cancer Therapeutics Market to Reach US$624.6 Million by 2030

The global market for Pet Cancer Therapeutics estimated at US$430.9 Million in the year 2024, is expected to reach US$624.6 Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$218.4 Million by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$117.4 Million While China is Forecast to Grow at 10.1% CAGR

The Pet Cancer Therapeutics market in the U.S. is estimated at US$117.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$128.6 Million by the year 2030 trailing a CAGR of 10.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Pet Cancer Therapeutics Market - Key Trends & Drivers Summarized

Why Is Cancer Care in Pets Emerging as a Priority in Veterinary Medicine?

Pet cancer therapeutics is evolving into one of the most dynamic segments in veterinary healthcare, driven by rising pet lifespans, increased veterinary expenditure, and a growing tendency among pet owners to pursue advanced care similar to human oncology. Cancer is the leading cause of death in older dogs and cats, with prevalent forms including lymphoma, mast cell tumors, osteosarcoma, melanoma, and hemangiosarcoma. As pet ownership becomes more emotionally and economically involved, there is a rising demand for early detection, effective treatment, and quality-of-life maintenance in companion animals diagnosed with cancer.

Diagnostics have improved markedly, with the availability of digital radiography, CT scans, fine-needle aspiration cytology, and immunohistochemistry in specialty clinics enabling early-stage identification and classification of tumors. This, in turn, has increased therapeutic uptake. Veterinary oncologists now have access to a wider arsenal of interventions, including chemotherapy, targeted drugs, immunotherapy, surgical oncology, and radiation therapy. These interventions were previously limited to university-affiliated centers but are now expanding into commercial veterinary chains and urban clinics.

Parallel developments in insurance coverage for pets, wellness plans, and pet-focused oncology diagnostics are fueling demand. Pet owners are increasingly seeking treatments that offer both curative intent and palliative care options. The convergence of human and veterinary oncology research, supported by cross-species trials and biomarker identification, is driving innovation and enabling translational therapies tailored to the veterinary market.

What Therapeutic Innovations Are Reshaping Veterinary Oncology?

The most notable shift in the pet cancer therapeutics market is the move from generic chemotherapeutic regimens to targeted and immunotherapeutic approaches. Monoclonal antibodies (e.g., Blontress and Tactress by Aratana Therapeutics) and small-molecule inhibitors are being used to target specific tumor antigens or growth pathways, improving survival and minimizing systemic toxicity. Tyrosine kinase inhibitors such as toceranib phosphate (Palladia) are now routinely used for mast cell tumors in dogs.

Immunotherapies, including cancer vaccines and checkpoint inhibitors, are emerging as adjunctive or standalone treatments. Canine melanoma vaccine (Oncept) has shown promise in extending survival in dogs with oral melanoma, and other autologous vaccine platforms are under development for hemangiosarcoma and lymphoma. Gene therapy is also under early investigation, with trials exploring vector-based tumor suppressor gene delivery and immune modulation.

On the diagnostics side, liquid biopsies and circulating tumor cell (CTC) detection are being explored as non-invasive tools to monitor tumor progression or recurrence. Digital health tools, such as AI-based symptom trackers and tele-veterinary consultations, are helping in early cancer symptom identification and post-treatment monitoring. These innovations are transforming the clinical landscape and enabling more customized, data-driven cancer management in pets.

Which Segments and Markets Are Leading in Pet Oncology Therapeutics Uptake?

Dogs remain the largest patient population for veterinary oncology, with significantly higher diagnosis and treatment rates than cats. Breeds such as Golden Retrievers, Boxers, and Bernese Mountain Dogs show genetic predisposition to certain cancers, leading to demand concentration in urban, high-income pet-owner clusters. Cats, though less frequently diagnosed, are seeing growing attention in feline-specific cancer therapeutics, especially for lymphoma and squamous cell carcinoma.

The highest market penetration exists in North America, particularly the United States, where advanced veterinary hospitals, oncology specialists, and insurance-backed services are widely available. Europe is following closely, with countries like the UK, Germany, and the Netherlands reporting high treatment adoption due to awareness and regulatory support for companion animal drugs. Asia-Pacific is a rapidly growing region, especially in Japan, South Korea, and urban centers in China and India, where pet humanization trends are triggering new investments in specialized care.

Veterinary clinics, pet hospitals, and diagnostic laboratories form the main supply chain. Specialty care centers that offer chemotherapy, radiation, and surgical oncology are growing in metropolitan areas. Pharma companies are increasingly targeting the veterinary oncology space with tailored R&D, while pet insurance providers are broadening coverage policies to include cancer therapies, diagnostics, and follow-up care.

What Is Driving Growth in the Global Pet Cancer Therapeutics Market?

The growth in the global pet cancer therapeutics market is driven by rising pet longevity, increasing willingness among owners to invest in advanced care, growing access to diagnostic and therapeutic technologies, and the emergence of targeted therapies and immuno-oncology in the veterinary sector. As pet humanization trends deepen, cancer treatment is transitioning from palliative support to proactive, precision-based interventions.

Expanding availability of pet insurance, increasing number of veterinary specialists, and rising prevalence of cancer due to better detection are accelerating therapeutic uptake. Regulatory support for veterinary drugs and streamlined clinical approval pathways are also enabling faster commercialization of novel therapies. The trend of translational research-leveraging human oncology advances to inform veterinary protocols-is further supporting innovation.

With oncology now a core pillar of veterinary specialization, the pet cancer therapeutics market is expected to continue its upward trajectory, supported by rising pet adoption rates, aging pet populations, and technological breakthroughs in drug delivery, tumor genetics, and personalized medicine.

SCOPE OF STUDY:

The report analyzes the Pet Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Therapy (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapies, Other Therapies); Animal (Dog, Cat, Other Animals); Application (Lymphoma Application, Mast Cell Cancer Application, Melanoma Application, Mammary & Squamous Cell Cancer Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• AB Science
• Akston Biosciences
• Anivive Lifesciences
• Boehringer Ingelheim
• Dechra Pharmaceuticals
• Elanco Animal Health
• ImpriMed
• Karyopharm Therapeutics
• LiteCure LLC
• Mars Petcare
• Merck Animal Health (MSD)
• Nippon Zenyaku Kogyo (Zenoaq)
• Norbrook Laboratories
• Oasmia Pharmaceuticals
• PetCure Oncology
• Pfizer (Zoetis)
• QBiotics Group Ltd.
• Regeneus Ltd.
• SpyBiotech
• VetDC Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more